2021
New nonchemotherapy treatment options for cutaneous T-cell lymphomas
Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Review Of Anticancer Therapy 2021, 21: 1017-1028. PMID: 33554707, DOI: 10.1080/14737140.2021.1882859.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeSézary syndromeMycosis fungoidesTreatment optionsNovel agentsCutaneous T-cell lymphomaCAR T-cell therapyAdditional novel agentsT-cell lymphomaT-cell therapyAntibody-based therapiesHistone deacetylase inhibitorsConventional chemotherapy approachesCheckpoint inhibitorsImmunomodulatory treatmentBrentuximab vedotinSystemic therapyAntibody agentsComplete responseLymph nodesTreatment armamentariumT cellsChemotherapy approachesImmune effectorsSmall molecule inhibitors
2002
Immunologic mechanisms of antitumor activity
Foss FM. Immunologic mechanisms of antitumor activity. Seminars In Oncology 2002, 29: 5-11. PMID: 12068382, DOI: 10.1053/sonc.2002.33076.Peer-Reviewed Original ResearchConceptsAntigen-presenting cellsCytotoxic T lymphocytesEffector cellsCostimulatory moleculesT lymphocytesImmune responseTumor antigensImmune effectorsTumor-specific cytotoxic T lymphocytesTumor cellsMHC complexesEffector cell expansionInadequate immune responseImmune effector cellsHost immune surveillanceAntigen class ICostimulatory adhesion moleculesTumor-associated peptidesT cell receptorOverall immunosuppressionCytokine therapyImmunologic mechanismsAdvanced cancerAntitumor responseTumor escape